Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Breast cancer : comprehensive management / / ; edited-in-chief Shashanka Mohan Bose ; Suresh Chander Sharma, Alok Mazumdar, Robin Kaushik, editors
| Breast cancer : comprehensive management / / ; edited-in-chief Shashanka Mohan Bose ; Suresh Chander Sharma, Alok Mazumdar, Robin Kaushik, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (601 pages) : illustrations |
| Disciplina | 616.99449 |
| Soggetto topico |
Breast - Cancer
Breast Neoplasms - therapy |
| ISBN |
981-16-4545-0
981-16-4546-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910743357203321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast cancer management
| Breast cancer management |
| Pubbl/distr/stampa | London : , : Future Medicine, , [2012]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.9944905 |
| Soggetto topico |
Breast - Cancer
Breast Neoplasms - therapy |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1758-1931 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910284447203321 |
| London : , : Future Medicine, , [2012]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast cancer management
| Breast cancer management |
| Pubbl/distr/stampa | London : , : Future Medicine, , [2012]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.9944905 |
| Soggetto topico |
Breast - Cancer
Breast Neoplasms - therapy |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1758-1931 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996321302303316 |
| London : , : Future Medicine, , [2012]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Breast Cancer Treatment : an interdisciplinary approach / / Nima Rezaei, editor
| Breast Cancer Treatment : an interdisciplinary approach / / Nima Rezaei, editor |
| Autore | Rezaei Nima |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (445 pages) |
| Collana | Interdisciplinary Cancer Research Series |
| Soggetto topico | Breast Neoplasms - therapy |
| ISBN |
9783031658273
9783031658266 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- About the Editor -- Signal Transducer and Activator of Transcription as a Potential Therapeutic Target in Breast Cancer -- 1 Introduction -- 2 STAT Family Members Characteristics, Activation, and Functional Development -- 2.1 STAT Family Members Expression and Activity in Breast Cancer -- 2.2 STAT1 and Breast Cancer -- 2.3 STAT2 and Breast Cancer -- 2.4 STAT3 and Breast Cancer -- 2.5 STAT4 and Breast Cancer -- 2.6 STAT5a/b and Breast Cancer -- 2.7 STAT6 and Breast Cancer -- 2.8 ER+ Breast Cancer Subtypes and STAT Signaling -- 2.9 HER2/Neu + Breast Cancer and STAT Signaling -- 2.10 TNBC and STAT Signaling -- 3 STAT Proteins: The Promising Targets in the Treatment of Breast Cancer -- 4 Conclusion -- References -- Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective -- 1 Introduction -- 2 Predictive Biomarkers, TILs, Genes and Their Roles in TNBC -- 3 Drug Resistance in TNBC -- 4 Systemic Therapy in TNBC -- 5 siRNA Therapy in TNBC -- 6 Conclusion -- References -- Advances in Local Ablative Techniques for Breast Cancer -- 1 Introduction -- 2 Overview of Local Ablative Techniques in Breast Cancer Management -- 3 Localization Techniques -- 4 Ablative Treatment Modalities for Curative Intent -- 4.1 Cryotherapy -- 4.2 Radiofrequency Ablation (RFA) in Breast Cancer Management -- 4.3 High-Intensity Focused Ultrasound (HIFU) -- 4.4 Microwave Ablation -- 4.5 Laser Therapy in Breast Cancer Management -- 5 Ablative Surgery in Palliative Settings -- 5.1 Local Therapy -- 5.2 Ablative Therapies Toward Metastatic Lesion(s) -- 5.2.1 Bone -- 5.2.2 Liver -- 5.2.3 Lung -- 5.2.4 Others -- 6 Conclusion -- References -- Radiotherapy in Breast Cancer -- 1 Introduction -- 2 History -- 3 Overview of Breast Cancer -- 3.1 Types -- 3.2 Breast Cancer Subtypes -- 3.2.1 Hormone Receptor-Positive Breast Cancer.
3.2.2 HER2-Positive Breast Cancer -- 3.2.3 Triple-Negative Breast Cancer -- 3.3 Risk Factors and Etiology -- 3.4 Pathophysiology -- 3.5 Signs and Symptoms -- 3.6 Diagnosis -- 3.7 Staging -- 3.8 Prognosis -- 4 Types of Radiation Therapy -- 5 Uses of Radiotherapy in Breast Cancer -- 6 Brachytherapy -- 7 Combination Therapy and Management of Breast Cancer -- 7.1 Chemotherapy -- 7.2 Targeted Therapy -- 7.3 Management of Non-invasive (In Situ) Breast Cancer -- 7.4 Management of Early Invasive Breast Cancer -- 7.5 Loco-Regional Radiotherapy -- 7.6 Axillary Radiotherapy -- 8 Adverse Effects of Radiation Therapy -- 9 Conclusion -- References -- Percutaneous Breast Cancer Treatment -- 1 Introduction -- 2 Cryoablation -- 3 Radiofrequency Ablation -- 4 Microwave Ablation -- 5 High-Intensity Focused Ultrasound (HIFU) -- 6 Laser Ablation -- 7 Conclusion -- References -- Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine -- 1 Introduction -- 2 Targeted Therapies -- 2.1 Hormone Receptor-Targeted Therapies -- 2.2 HER2-Targeted Therapies -- 2.3 Cell Cycle-Targeted Therapies -- 3 Immunotherapy -- 3.1 Immune Checkpoint Inhibitors -- 3.2 Cancer Vaccines -- 4 Precision Medicine -- 5 Other Emerging Therapies -- 5.1 Oncolytic Viruses -- 5.2 PARP Inhibitors -- 6 Personalized Treatment Approaches -- 6.1 Integration of Genomic and Clinical Data -- 6.2 Development of Decision Support Tools -- 7 Nanotechnology in Breast Cancer Treatment -- 7.1 Folic Acid-Engineered Nanocarriers -- 7.2 Antineoplastic Biogenic Gold Nanoparticles -- 7.3 Lipid-Based Nanoparticles (LNPs) -- 7.4 Curcumin Nanoparticles -- 7.5 Antibody-Conjugated Polymeric Nanoparticles -- 8 Other Treatment Strategies -- 8.1 Liquid Biopsies -- 8.2 Artificial Intelligence -- 9 Role of Modern Bioinformatics in the Treatment of Breast Cancer. 10 Role of CRISPR Gene Editing in Treating Breast Cancer -- 11 Conclusion -- References -- Updates on the Management of Ductal Carcinoma In Situ of the Breasts -- 1 Introduction -- 2 Breast Cancer Screening and Diagnosis of DCIS -- 3 Classification Systems of DCIS -- 4 Challenges in Histopathological Diagnosis -- 5 Paradigm Change of the Current Standard of Care -- 6 Treating DCIS or Treating Patients with DCIS? -- 7 Clinical Factors to Be Considered When Treating Low-Risk DCIS -- 8 Conclusion -- References -- Nanostructured Lipid Carrier as a Strategy for the Treatment of Breast Cancer -- 1 Introduction -- 2 Conventional Treatment of Breast Cancer -- 2.1 Lipidic Nanoparticle as a Strategy for the Treatment of Breast Cancer -- 2.2 Nanostructured Lipid Carriers as a Strategy for the Treatment of Breast Cancer -- 3 Cancer Drug-Loaded NLC -- 3.1 Anthracycline-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.2 Taxane-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.3 Antagonist of Estrogen Receptor-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.4 HIT, LEAD, or Drug Candidate-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.5 Multidrug-Loaded NLC as a Strategy for the Treatment of Breast Cancer -- 3.6 Developing Theory -- 3.7 Stimuli-Responsive NLC as a Strategy for the Treatment of Breast Cancer -- 4 New Trends: Functionalized CLN -- 5 Conclusion -- References -- Managing Breast Cancer Using the Cell-Surface GRP78 -- 1 Introduction -- 1.1 Targeting GRP78 for Early Detection and Diagnosis -- 1.2 Modulating GRP78 Expression for Therapeutic Intervention -- 1.3 GRP78 as a Prognostic Indicator and Monitoring Tool -- 1.4 GRP78 Mediates Cell Survival and Apoptosis -- 1.5 Challenges and Future Prospects -- 2 Conclusion -- References. A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer -- 1 Introduction -- 2 Current Guidelines for HT, IT, and Their Combination in Advanced Breast Cancer -- 2.1 Systemic Therapy in the Adjuvant Setting (Table 1) -- 2.2 Systemic Therapy in Locoregional Recurrent or Stage IV (M1) Breast Cancer (Table 2) -- 3 Experimental Studies Suggest a Close Relationship Between Tumor Growth and the G0-G1 State and Immune Evasion -- 3.1 Tumor Growth and Immune Evasion -- 3.2 G0-G1 State and Immunosuppressive TME Reversion Induced by Antiestrogens -- 4 Usefulness of Maintenance IT in Patients Showing Clinical Benefit During Conventional CT or with Minimal Residual Disease (M... -- 5 A Prolonged Antiestrogen-Induced G0-G1 State Concomitant with an Increased Cytotoxic Immune Response During a New Schedule o... -- 6 The Potential Rationale of a New HIT Schedule -- 7 Conclusion -- References -- Discovering New Targets in Triple-Negative Breast Cancer (TNBC): The Androgen Receptor and the Estrogen Receptor β -- 1 Introduction -- 2 Triple-Negative Breast Cancer -- 2.1 TNBC Therapies -- 2.2 Targeted Therapies -- 2.3 Immunotherapy -- 2.4 AR in Triple-Negative Breast Cancer -- 2.4.1 AR: Structure and Function -- 2.4.2 AR in Breast Cancer: An Overview -- 2.4.3 The Role of AR in TNBC -- 2.4.4 Androgen Targeted Therapies -- 2.5 Estrogen Receptor β in Triple-Negative Breast Cancer -- 2.5.1 Estrogen Receptor β: Generalities -- 2.5.2 The Role of ERβ in BC: An Overview -- 2.5.3 The Role of ERβ in Triple-Negative Breast Cancer -- 2.5.4 Estrogen Receptor β Targeted Therapy in TNBC -- 3 Concluding Remarks -- References -- Growth Factor Receptor Implications in Breast Cancer: Prospects for Their Molecular Transactivation in the Future and Obstacle... -- 1 Introduction -- 1.1 Incidence -- 1.2 Risk Factors -- 2 Definition and Molecular Classification of BC. 2.1 BC Classification -- 2.2 Histological Subtypes -- 2.3 Molecular Subtypes -- 2.4 Estrogen Receptor (ER) -- 2.5 Nuclear ER -- 2.6 Membranal ER -- 2.7 Relationship Between ER and HER2 -- 3 Receptor Tyrosine Kinases -- 3.1 Structure and Classification -- 3.2 Role of Receptor Tyrosine Kinase (RTK) Signaling in BC Progression: MAPKs and PI3K/Akt Signaling Pathways -- 3.2.1 Signaling Pathways -- 3.2.2 Mitogen-Activated Protein Kinase Pathway (MAPK) -- 3.2.3 ERK Cascade -- 3.2.4 JNK Cascade -- 3.2.5 p38 Cascade -- 3.2.6 Phosphoinositide 3-Kinase/Akt Pathway (PI3K/Akt) -- 3.2.7 Janus Kinase/Signal Transducer and Activator of Transcription Pathway (JAK/STAT) -- 3.2.8 Notch Signaling Pathway -- 3.2.9 Nuclear Factor-Kappa B Pathway (NF-κB) -- 3.2.10 Src Family Kinases -- 4 Participation of Specific RTKs in BC -- 4.1 RTKs and BC -- 4.2 Role of Epidermal Growth Factor Receptor (EGFR) in BC -- 4.3 Role of HER2 in BC -- 4.4 Role of Insulin Receptor (IR) in BC -- 4.5 Role of Insulin-Like Growth Factor Receptor Type 1 (IGF-1R) in BC -- 4.6 Role of Vascular Endothelial Growth Factor Receptor (VEGR) in BC -- 4.7 Role of Platelet-Derived Growth Factor Receptor (PDGFR) in BC -- 4.8 Role of Fibroblast Growth Factor Receptor (FGFR) in BC -- 4.9 Role of Hepatocyte Growth Factor (HGF)/MET Receptor in BC -- 5 RTK Transactivation by GPCRS and Nuclear Receptors -- 5.1 GPCRs -- 5.2 GPCR-Mediated Transactivation of RTKs -- 5.3 GPCRS in Cancer and BC -- 5.4 RTK Transactivation by Specific GPCRs in BC -- 5.4.1 Estrogens/GPER1 -- 5.4.2 Chemokine Receptors -- 5.4.3 Cannabinoid Receptor 2 -- 5.4.4 Lysophosphatidic Acid (LPA) Receptors (LPARs) -- 5.4.5 Protease-Activated Receptors -- 6 Blocking GPCRS-RTKs Transactivation, Therapeutic Strategies with a Clinical Approach -- References -- Addressing ESR1 Mutation: A Key Factor in Hormone Therapy Resistance in Breast Cancer. 1 Introduction. |
| Record Nr. | UNINA-9910874667903321 |
Rezaei Nima
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Modern breast cancer imaging / / Su Jin Kim Hsieh, Elizabeth Anne Morris, editors
| Modern breast cancer imaging / / Su Jin Kim Hsieh, Elizabeth Anne Morris, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (466 pages) |
| Disciplina | 616.99449075 |
| Soggetto topico |
Breast - Cancer
Breast - Cancer - Treatment Technological innovations Breast Neoplasms - diagnostic imaging Breast Neoplasms - therapy Image Processing, Computer-Assisted |
| ISBN | 3-030-84546-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Contents -- Contributors -- Part I: Updates in Clinical and Pathological Aspects for Breast Cancer -- Chapter 1: Molecular Basis of Breast Cancer -- 1.1 Introduction -- 1.2 BC (Basal Carcinomas) and TNC (Triple Negative Carcinomas) -- 1.3 Luminal Carcinomas (LC) -- 1.4 HER2-Enriched Carcinomas -- References -- Chapter 2: Risk Factors for Breast Cancer -- 2.1 Introduction -- 2.2 Gender and Age -- 2.3 Reproductive Factors -- 2.4 Gestation and Lactation -- 2.5 Contraception and Hormone Replacement Therapy -- 2.6 Obesity -- 2.7 Alcohol and Smoking -- 2.8 Thoracic Radiation Therapy -- 2.9 Precursor Injuries -- 2.10 Hereditary Syndromes and Breast Cancer -- 2.11 Genes and Associated Syndromes -- 2.11.1 Genes Associated with High Penetrance -- 2.11.2 Genes Associated with Moderate Penetrance -- 2.12 Quantification of Mutation Risk -- 2.13 Genetic Testing for High-Risk Patients -- References -- Chapter 3: Genomic Tests -- 3.1 Introduction -- 3.2 Gene Expression Assays -- 3.2.1 Oncotype DX -- 3.2.2 MammaPrint -- 3.2.3 Other Assays -- 3.3 Concordance of Expression Assays -- 3.4 Conclusion -- References -- Chapter 4: Updates in Surgical Approaches for Breast and Axilla -- 4.1 Introduction -- 4.2 Axillary Management in Clinically Node-Negative Patients with Invasive Breast Cancer -- 4.3 Axillary Management in Micrometastases (N1m1) or Isolated Tumor Cells N (+1) Patients with Invasive Breast Cancer -- 4.4 Axillary Management in Clinically Node-Negative Patients and Macrometastases in the Pathology with Invasive Breast Cancer -- 4.5 Axillary Management in Clinically Node-Positive Patients and Neoadjuvant Chemotherapy (NAC) Treatment -- References -- Chapter 5: Pathological Aspects for Diagnosis -- 5.1 Pre-analytical Procedures -- 5.2 Radiological-Pathological Correlation -- 5.3 Fibroepithelial Lesions -- 5.4 Papillary Neoplasms.
5.5 Benign High-Risk Lesions and Precursors, Including Classic Lobular Intraepithelial Neoplasia -- 5.6 Atypical Ductal Hyperplasia and Low-Grade Carcinoma In Situ -- 5.7 Intermediate and High-Grade Ductal Carcinoma In Situ -- 5.8 Pleomorphic Lobular Carcinoma In Situ (PLCIS) -- 5.9 Biomarkers in Ductal Carcinoma In Situ -- 5.10 Invasive Carcinoma of No Special Type -- 5.11 Macroscopic Evaluation of the Breast Specimen, Including Those with Neoadjuvant Treatment -- 5.12 Special Subtypes -- 5.13 Special Methods -- 5.13.1 Immunohistochemistry -- 5.13.2 In Situ Hybridization -- 5.14 Next-Generation Sequencing (NGS) -- References -- Part II: Update in Imaging Method -- Chapter 6: Radiation Based Imaging: Digital Mammography, Tomosynthesis -- 6.1 Introduction -- 6.2 Technique -- 6.3 Indications -- 6.4 Interpretation -- 6.4.1 Breast Composition -- 6.4.2 Masses -- 6.4.3 Calcifications -- 6.4.4 Architectural Distortion -- 6.4.5 Asymmetries -- 6.4.6 Intramammary Lymph Node -- 6.4.7 Skin Lesions -- 6.4.8 Single Dilated Duct -- 6.4.9 Associated Findings -- 6.4.10 Location of Lesions -- 6.4.11 ACR-BI-RADS® Final Assessment -- 6.4.12 Recommendation -- 6.5 Conclusions -- References -- Chapter 7: Sonographic Based Imaging: Ultrasound, Color Doppler, Elastography, and Automated Breast Imaging -- 7.1 Introduction -- 7.2 Scanning Technique -- 7.2.1 The Ideal Image -- 7.2.2 Anatomy -- 7.2.3 Harmonic -- 7.2.4 Compound Imaging -- 7.3 Doppler Evaluation -- 7.4 Elastography -- 7.4.1 Strain Elastography -- 7.4.2 Shear Wave Elastography -- 7.5 Automated Breast Ultrasound -- 7.6 Correlation with Other Imaging Methods -- 7.7 Exam Documentation -- 7.8 BI-RADS® Lexicon -- 7.9 Report and Assessment -- 7.9.1 BI-RADS® Categories -- References -- Chapter 8: Magnetic Resonance Imaging: Regular Protocols and Fast Protocols -- 8.1 Introduction -- 8.2 Standard Examination. 8.3 T2-Weighted Images -- 8.4 T1-Weighted Images -- 8.5 Subtraction, Enhancement Curve, and 3D MIP -- 8.6 Diffusion-Weighted Images -- 8.7 Breast Implants -- 8.8 Abbreviated Protocol -- 8.9 Ultrafast Breast MRI -- 8.10 Conclusion -- References -- Chapter 9: Nuclear Medicine Based Methods: PET FDG and Other Tracers -- 9.1 Introduction -- 9.1.1 Basic Aspects of 18F-FDG-PET -- 9.2 18F-FDG-PET/CT Indications in Breast Cancer -- 9.2.1 Primary Breast Tumor Detection and Staging (T) -- 9.2.2 Nodal Staging (N) -- 9.2.3 Metastatic Staging (M) -- 9.2.4 Recurrence -- 9.2.5 Response Assessment to Neoadjuvant Chemotherapy (NAC) -- 9.2.6 Response Assessment in Metastatic Disease -- 9.3 Prognostic Value -- 9.4 Other PET Technologies and Tracers -- 9.4.1 PET/MR and Positron Emission Mammography (PEM) -- 9.4.2 Non-FDG Tracers for Breast Cancer -- 9.5 Conclusion -- References -- Chapter 10: Image-Guided Percutaneous Biopsies -- 10.1 Historical Perspective -- 10.2 Understanding Imaging-Guidance and Needle Selection: Practical Considerations -- 10.3 Pre-biopsy Assessment -- 10.4 Patient Preparation, Biopsy Risks, and General Post-biopsy Information -- 10.5 Considerations Regarding Clip Placement -- 10.6 Clip Placement Complications -- 10.7 Ultrasound-Guided Biopsy -- 10.8 Fine-Needle Aspiration (FNA) -- 10.8.1 Axillary Assessment -- 10.8.2 Cysts -- 10.8.3 Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) -- 10.8.4 Challenging Lesion Location -- 10.8.5 Diagnostic Accuracy and Availability -- 10.9 Technique -- 10.10 Complications and Post-care -- 10.10.1 Ultrasound-Guided Core Needle Biopsy and Vacuum-Assisted Biopsy -- 10.10.2 Sampling Considerations -- 10.11 Quantity and Quality of the Sample -- 10.12 Adequate Targeting -- 10.13 Choosing Between VAB and CNB -- 10.13.1 Therapeutic VAB -- 10.13.2 VAB and CNB Technique -- 10.14 Mammography-Guided Biopsy. 10.15 Stereotactic Biopsy -- 10.16 Upright Add-On and Prone Table Biopsy Systems -- 10.17 The Procedure -- 10.18 Digital Breast Tomosynthesis-Guided Biopsy -- 10.19 DBT Versus Stereotactic Guided Biopsy -- 10.20 The Procedure -- 10.21 Technical Challenges and Possible Solutions (DBT and Stereotactic Biopsy) -- 10.21.1 Subtle Findings -- 10.21.2 Far Posterior Lesions -- 10.21.3 Thin Breasts -- 10.22 Superficial Lesions -- 10.23 MRI-Guided Biopsy -- 10.23.1 Second-Look Ultrasound and Second-Look Mammography -- 10.23.2 Second-Look Mammography -- 10.23.3 The Procedure -- 10.23.4 Complications and Post-biopsy Care -- 10.24 Imaging-Pathology Correlation -- 10.25 Discordant Biopsy -- 10.25.1 Concordant Malignancy -- 10.25.1.1 Discordant Malignancy -- 10.25.2 Concordant Benign -- 10.25.3 Discordant Benign -- 10.25.4 High-Risk and Borderline Lesions -- References -- Chapter 11: Breast Imaging Preoperative Localization Procedure -- 11.1 Introduction -- 11.2 Indications of Preoperative Localization -- 11.3 Pre-procedure Review of Preoperative Localization -- 11.4 Wire Localization -- 11.4.1 MG-Guided and Stereotactic-Guided Wire Localization -- 11.4.1.1 Technique Using a Perforated or Marked Compression Plate -- 11.4.1.2 Technique Using a Stereotactic Table -- 11.4.2 US-Guided Wire Localization -- 11.4.3 MRI-Guided Wire Localization -- 11.4.4 Wire Variations -- 11.5 Nonwire Localization Methods -- 11.5.1 Carbon Marking -- 11.5.2 Radio-Guided Occult Lesion Localization (ROLL) -- 11.5.2.1 Sentinel Node and Occult Lesion Localization (SNOLL) -- 11.5.3 Current Lesion Localization Techniques -- 11.5.3.1 Radioactive Nonwire Localization Device -- Radioactive Seed Localization -- 11.5.3.2 Non-radioactive Wireless Localization Devices -- Radar Reflector Localization -- Magnetic Seed Localization -- Radiofrequency Identification Tag (RFID) Localization. 11.6 Post-procedure Complications -- 11.7 Post-procedure Assessment -- References -- Part III: Different Clinical Scenario: Clinical Management and Role of Imaging Modalities -- Chapter 12: Screening -- 12.1 Introduction -- 12.2 Screen-Film Mammography -- 12.3 Digital Mammography -- 12.4 Tomosynthesis -- 12.5 Magnetic Resonance Imaging (MRI) -- 12.6 Ultrasound -- 12.7 Molecular Breast Imaging -- 12.8 Clinical Breast Examination -- 12.9 Breast Self-Examination -- 12.10 Thermography -- 12.11 Elastography -- 12.12 Screening in Special Populations -- 12.12.1 Increased Breast Density -- 12.12.2 High-Risk of Breast Cancer -- 12.12.3 Elderly Women -- References -- Chapter 13: Diagnostic -- 13.1 Diagnostic Management of Clinical Situations -- 13.1.1 Palpable Changes of the Breast -- 13.1.1.1 Breast Lump -- 13.1.1.2 Paget Disease -- 13.1.1.3 Occult Breast Cancer and Axillary Lymphadenopathy -- 13.1.2 Non-palpable Breast Changes -- 13.1.2.1 Image Screening Findings -- 13.1.2.2 Nipple Discharge -- 13.1.3 Breast Biopsy in Clinical Scenario -- 13.1.3.1 US and Mammography-Guided Biopsy (Fine-Needle Aspiration (FNA)/Core-Needle Biopsy (CNB)/Vacuum Aspiration Biopsy (VAB)) -- 13.1.3.2 MRI- and DBT-Guided Biopsy -- References -- Chapter 14: Preoperative (Breast) -- 14.1 Preoperative Tests for the Breast -- 14.1.1 Imaging Methods -- 14.1.1.1 Mammography -- 14.1.1.2 Ultrasound -- 14.1.1.3 Tomosynthesis -- 14.1.1.4 Breast Magnetic Resonance Imaging -- 14.1.1.5 Positron Emission Tomography-Computed Tomography (PET-CT) -- 14.2 Preoperative Tests for the Axilla -- 14.2.1 Indications -- 14.2.2 Methods -- 14.2.2.1 Ultrasound -- 14.2.2.2 Mammography -- 14.2.2.3 Magnetic Resonance Imaging -- 14.2.2.4 PET-CT -- 14.3 Case Examples -- 14.3.1 Case 1 -- 14.3.2 Case 2 -- 14.3.3 Case 3 -- 14.3.4 Case 4 -- 14.3.5 Case 5 -- References. Chapter 15: Systemic Staging (Total Body - When, How). |
| Record Nr. | UNINA-9910523804803321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
